0001140361-18-035317.txt : 20180803 0001140361-18-035317.hdr.sgml : 20180803 20180803112537 ACCESSION NUMBER: 0001140361-18-035317 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180803 DATE AS OF CHANGE: 20180803 EFFECTIVENESS DATE: 20180803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vedantra Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001555192 IRS NUMBER: 452966790 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-318453 FILM NUMBER: 18990826 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 WEST, SUITE 14303 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-360-9995 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BUILDING 1400 WEST, SUITE 14303 CITY: CAMBRIDGE STATE: MA ZIP: 02139 D 1 primary_doc.xml X0708 D LIVE 0001555192 Vedantra Pharmaceuticals, Inc. ONE KENDALL SQUARE BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 617-360-9995 DELAWARE None None Corporation true Daniel Geffken c/o Vedantra Pharmaceuticals, Inc. BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 Executive Officer Director Mr. Geffken is the Chief Financial Officer of the Issuer. Julian Adams c/o Vedantra Pharmaceuticals, Inc. BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 Director Mr. Adams is the Executive Chairman of the Board of Directors of the Issuer. Isaac Blech c/o Vedantra Pharmaceuticals, Inc. BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 Director Satish Jindal c/o Vedantra Pharmaceuticals, Inc. BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 Director William Koster c/o Vedantra Pharmaceuticals, Inc. BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 Director Isaac Kohlberg c/o Vedantra Pharmaceuticals, Inc. BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 Director Frank Haluska c/o Vedantra Pharmaceuticals, Inc. BUILDING 1400 WEST, SUITE 14303 CAMBRIDGE MA MASSACHUSETTS 02139 Director Biotechnology Decline to Disclose 06b false 2018-07-20 false true true Convertible Promissory Notes false 0 None None Maxim Merchant Capital 120708 405 LEXINGTON AVENUE New York NY NEW YORK 10174 All States false 14492501 14492501 0 false 115 1449250 true 0 The persons named in Item 12 will receive a commission of 10% of the gross proceeds of the offering. 0 false Vedantra Pharmaceuticals, Inc. /s/ Daniel Geffken Daniel Geffken Chief Financial Officer of the Issuer 2018-08-03